These instruments complement two ASTar units already deployed for evaluations that have been successfully completed in Kuwait and UAE. Demand for ASTar has increased across the region following successful commercialisation efforts by AMICO. It is anticipated that the first ASTar will move into routine clinical use in the region during Q2 2026 with several more expected to go live later in the year.

“The instruments will be installed in two leading health systems in Riyadh and Jeddah with the expectation they will help guide adoption decisions for the Ministry of Health”, says Sherif Harydi, Regional Commercial Director for AMICO.

“We are excited to introduce ASTar to Saudi Arabia where we see significant interest in the technology to meet patient needs”, adds Franco Pellegrini, VP EMEA Sales for Q-linea.

About AMICO
AMICO is a leading regional healthcare commercial corporation and in‑vitro diagnostics (IVD) distributor with a strong presence across the Middle East, operating in 13 countries and serving the region for more than forty years. With a clear mission to bridge the gap between cutting‑edge diagnostic technologies and the diverse needs of healthcare systems in the Middle East, AMICO plays a central role in accelerating access to advanced solutions across the GCC and wider region.

AMICO’s partnership with Q‑linea reflects its commitment to delivering impactful, clinically relevant IVD technologies—particularly in the critical area of sepsis management—supporting hospitals and laboratories in improving antimicrobial stewardship and advancing patient outcomes.